Cardiovascular DiseasesNCT00005252
Physicians' Health Study: Study of Low Cardiovascular Disease Mortality
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To explain the extremely low cardiovascular mortality among Physicians' Health Study (PHS) participants by ascertaining all cardiovascular and total deaths among the 90,457 physicians who returned enrollment forms but were not randomized into the study. Read more about this study
- Who is it for?
- Ages Up to 100 years, men only
- Conditions the study is for
- Cardiovascular Diseases, Heart Diseases, Coronary Disease
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Jan 1990to Dec 1992
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 100 years
- Men only
- No healthy volunteers
- Child, Adult, Older adult
No eligibility criteria
About this study
To explain the extremely low cardiovascular mortality among Physicians' Health Study (PHS) participants by ascertaining all cardiovascular and total deaths among the 90,457 physicians who returned enrollment forms but were not randomized into the study. Also, to compare the mortality experience of randomized physicians with various subgroups of non-participants.
Read the detailed description
BACKGROUND:
The Physicians' Health Study was a randomized, double-blind, placebo-controlled primary prevention trial designed to test whether 325 mg aspirin every other day reduced the risk of cardiovascular disease and whether 50 mg beta-carotene on alternate days decreased cancer incidence among 22,071 male physicians, aged 40-84 years in 1982. On December 18, 1987, the external Data Monitoring Board recommended early termination of the blinded aspirin component of the trial, based on the emergence of a statistically extreme benefit of aspirin on both fatal and nonfatal myocardial infarction, as well as the extraordinarily low cardiovascular mortality rates among study participants.
DESIGN NARRATIVE:
In January 1982, the Physicians' Health Study investigators purchased a tape from the American Medical Association that contained the names of all male physicians born between January 1, 1907 and December 31, 1942. The tape provided the basis for the invitation to join the trial. A new computer tape was purchased from the AMA that contained names, addresses, and dates of birth for all physicians registered as of December 1982, current and 1982 addresses, and any reported deaths. This tape was matched against Physician Health Study data files to eliminate those not on the original tape, as well as those known to be deceased at the time of the original mailing. When the match was complete, the results were a new tape that included names, most recent addresses, and dates of birth of all those who were invited to participate in the trial. A new master study tape was compiled that included all non-randomized potentially eligible respondents to the invitational mailing as well as a 35 percent random sample of the non-respondents. This group of 138,460 comprised the cohort. The National Death Index (NDI) was searched from January 1, 1982 to January 25, 1988, the official termination date of the trial for each physician in the cohort as well as for the 22,071 randomized participants. A copy of the death certificate was obtained from the state department of vital statistics for each death identified by the NDI in order to distinguish between vascular and non-vascular deaths. An Endpoints Committee, using death certificates and medical records in some cases, assigned the cause of death to be entered into the data base.
Analyses were performed comparing: all randomized versus all non-randomized respondents; those randomized versus those eligible but unwilling to participate; those randomized versus those initially willing and eligible who enrolled in an 18 week period but were excluded prior to randomization. Baseline data on the enrollment forms were examined to determine whether differences in mortality rates could be explained by differences in cardiovascular risk factors among the groups.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
- Medical subject headings
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startJan 1990
- Study completionDec 1992
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Investigators
- Julie Buring, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005252
- Sponsor's protocol ID
- 1134
- Other IDs
- R01HL042441
- Status last verified
- Aug 2004
- First submitted
- 25 May 2000
- Last updated
- 16 Mar 2016
- Results posted
- No
Publications
Ridker PM, Manson JE, Goldhaber SZ, Hennekens CH, Buring JE. Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. Am J Cardiol. 1992 Jul 1;70(1):10-3. doi: 10.1016/0002-9149(92)91381-d.
PubMed 1615847Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, Manson JE, Hennekens CH, Buring JE. Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort. J Am Coll Cardiol. 2000 Jan;35(1):96-105. doi: 10.1016/s0735-1097(99)00531-8.
PubMed 10636266Liu S, Sesso HD, Manson JE, Willett WC, Buring JE. Is intake of breakfast cereals related to total and cause-specific mortality in men? Am J Clin Nutr. 2003 Mar;77(3):594-9. doi: 10.1093/ajcn/77.3.594.
PubMed 12600848
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physicians' Health Study: Study of Low Cardiovascular Disease Mortality
- ClinicalTrials.gov ID
- NCT00005252
- Acronym / sponsor ID
- 1134
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Jan 1990
- Study completion
- Dec 1992 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explain the extremely low cardiovascular mortality among Physicians' Health Study (PHS) participants by ascertaining all cardiovascular and total deaths among the 90,457 physicians who returned enrollment forms but were not randomized into the study. Also, to compare the mortality experience of randomized physicians with various subgroups of non-participants.
Detailed description
BACKGROUND:
The Physicians' Health Study was a randomized, double-blind, placebo-controlled primary prevention trial designed to test whether 325 mg aspirin every other day reduced the risk of cardiovascular disease and whether 50 mg beta-carotene on alternate days decreased cancer incidence among 22,071 male physicians, aged 40-84 years in 1982. On December 18, 1987, the external Data Monitoring Board recommended early termination of the blinded aspirin component of the trial, based on the emergence of a statistically extreme benefit of aspirin on both fatal and nonfatal myocardial infarction, as well as the extraordinarily low cardiovascular mortality rates among study participants.
DESIGN NARRATIVE:
In January 1982, the Physicians' Health Study investigators purchased a tape from the American Medical Association that contained the names of all male physicians born between January 1, 1907 and December 31, 1942. The tape provided the basis for the invitation to join the trial. A new computer tape was purchased from the AMA that contained names, addresses, and dates of birth for all physicians registered as of December 1982, current and 1982 addresses, and any reported deaths. This tape was matched against Physician Health Study data files to eliminate those not on the original tape, as well as those known to be deceased at the time of the original mailing. When the match was complete, the results were a new tape that included names, most recent addresses, and dates of birth of all those who were invited to participate in the trial. A new master study tape was compiled that included all non-randomized potentially eligible respondents to the invitational mailing as well as a 35 percent random sample of the non-respondents. This group of 138,460 comprised the cohort. The National Death Index (NDI) was searched from January 1, 1982 to January 25, 1988, the official termination date of the trial for each physician in the cohort as well as for the 22,071 randomized participants. A copy of the death certificate was obtained from the state department of vital statistics for each death identified by the NDI in order to distinguish between vascular and non-vascular deaths. An Endpoints Committee, using death certificates and medical records in some cases, assigned the cause of death to be entered into the data base.
Analyses were performed comparing: all randomized versus all non-randomized respondents; those randomized versus those eligible but unwilling to participate; those randomized versus those initially willing and eligible who enrolled in an 18 week period but were excluded prior to randomization. Baseline data on the enrollment forms were examined to determine whether differences in mortality rates could be explained by differences in cardiovascular risk factors among the groups.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Study design
Who may qualify
- Ages
- Up to 100 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2016.
- Background: PubMed 1615847Ridker PM, Manson JE, Goldhaber SZ, Hennekens CH, Buring JE. Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. Am J Cardiol. 1992 Jul 1;70(1):10-3. doi: 10.1016/0002-9149(92)91381-d.
- Background: PubMed 10636266Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, Manson JE, Hennekens CH, Buring JE. Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort. J Am Coll Cardiol. 2000 Jan;35(1):96-105. doi: 10.1016/s0735-1097(99)00531-8.
- Background: PubMed 12600848Liu S, Sesso HD, Manson JE, Willett WC, Buring JE. Is intake of breakfast cereals related to total and cause-specific mortality in men? Am J Clin Nutr. 2003 Mar;77(3):594-9. doi: 10.1093/ajcn/77.3.594.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julie Buring
Brigham and Women's Hospital
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005252, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2016.